Project Echo
Confidential summary for informational purposes only — not an offer or solicitation. Details provided to qualified parties upon request/NDA.
Opportunity
A pharmaceutical company established in 1997, specializing in OTC products,
effervescent tablets, food supplements, medical devices, chewables, and ODTs, offers
contract manufacturing and private label services, with a 2022–2025 strategy focused on
expanding its own product range, strengthening commercial presence in CIS, EU, Baltic, and
Scandinavian markets, seeking partners for novel-technology drug development, and scaling
CMO services following recent investment in a new biotech facility, achieving €2M net
revenue but -€0.4M EBITDA in 2022 due to that capex.
Company Profile
Established in 1997, this pharmaceutical company specializes in OTC products, effervescent tablets, food supplements, medical devices, chewables, and orally disintegrating tablets (ODT). It provides full contract manufacturing (CMO) and private label services, producing both inhouse and external products with a focus on high-quality, innovative dosage forms.
Growth Focus
Actively expanding its own product range while strengthening commercial and business development functions to penetrate key markets. The company is seeking strategic partners for co-development and production of novel-technology-based drugs, with emphasis on R&D for new products, scaling CMO services, and broadening the geography of international partners and clients.
Financial Highlights
Net revenue of $2.5 million, with EBITDA of -$0.4 million in 2022, reflecting a temporary loss driven by significant investment in a new biotech facility to support future capacity and capability expansion in advanced manufacturing.
Investment
This established manufacturer offers an attractive platform for strategic investment or acquisition: a specialized producer in effervescent and innovative OTC/supplement forms with CMO/private label expertise, ongoing geographic and product expansion strategy, recent infrastructure upgrades via biotech investment, and strong potential for growth through partnerships in emerging European and neighboring markets.